Rigaku Holdings (268A) · InitiativeRestatedLatest Other Disclosures (2026-09-25): "Advanced"
Research and Development Investment and Open Innovation
First written in FY2024. 5 of 8 entries say "Advanced", first in FY2025. Latest entry: 2026-09-25.
8entries
2years
4from disclosures
How it moved
Same theme, other companies
Open-Innovation R&D Centered on X-Ray Analytical TechnologyA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2026-H1RestatedAnnual report
「Total R&D expenditure for the interim consolidated accounting period was ¥3,886 million.」
Total R&D expenditure in the first half of 2026 was ¥3,886 million, and the Group continued strategic investment including R&D. No new results such as commercialization of new products were disclosed in this filing. - FY2025AdvancedAnnual report
「The Group’s total R&D expenditure in the fiscal year ended December 2025 was ¥7,355 million, and the R&D expenditure ratio was 7.8%.」
R&D expenditure was ¥7,355 million and the R&D expenditure ratio was 7.8%. The Group commercialized or began selling new products and functions including XTRAIA XD-3300, XHEMIS TX-3000, Qualana, XTRAIA MF-3400 and ONYX3200. - FY2025-H1RestatedAnnual report
「Total R&D expenditure for the interim consolidated accounting period was ¥3,520 million.」
The Group continued its R&D activities and disclosed total R&D expenditure of ¥3,520 million for the first half of 2025. - FY2024First statedAnnual report
「We are actively promoting open innovation to strengthen the Group’s technological capabilities.」
The Group promotes R&D investment in core X-ray technologies, research into advanced analytical technologies and new application fields, intellectual property protection, and open innovation through partnerships and M&A with universities, research institutions and companies. The R&D expenditure ratio was 7.5% in the fiscal year ended December 2024.